Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft Versus Host Disease

Trial Profile

Randomized Phase II Study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft Versus Host Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belumosudil (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use

Most Recent Events

  • 20 Nov 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2023 to 20 Dec 2023.
  • 01 Nov 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jan 2024 to 1 Dec 2023.
  • 01 Nov 2023 Planned initiation date changed from 1 Jan 2024 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top